Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
胰岛素-胰高血糖素共轭物包括具有在胰高血糖素样1(GL
P-1)受体、胰高血糖素(
GCG)受体和/或胃抑制性蛋白(GIP)受体上激动剂活性的肽与具有在
胰岛素受体上激动剂活性的
胰岛素分子结合,以及利用这些共轭物治疗代谢性疾病,例如2型糖尿病。